Pro-inflammatory biomakers in depression: Treatment with venlafaxine
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
High levels of pro-inflammatory biomarkers have been reported in depression. In the present study, five pro-inflammatory biomarkers were measured in the blood of patients with major depressive disorder (MDD). Biomarker levels were compared to age- and sex-matched healthy subjects. Patients with MDD had significantly higher baseline levels of tumour necrosis factor-alpha (TNFalpha, P=0.04), interleukin-1beta (IL1beta, P=0.03), and monocyte chemotactic protein-1 (MCP-1; P=0.02) compared to controls. There were no differences between groups in levels of cell determinant-40 ligand (CD40L) and C-reactive protein (CRP). A subset of the MDD patients consented to undergo treatment with venlafaxine (an SNRI: at lower doses a selective serotonin reuptake inhibitor; at higher doses also a norepinephrine reuptake inhibitor) for 8 weeks. By week 8, all treatment completers had responded therapeutically. However, levels of TNFalpha, IL1beta, and MCP-1 remained elevated. A concave quadratic equation described the associations between plasma venlafaxine concentrations and IL1beta (P=0.03), TNFalpha (P=0.09), and MCP-1 (P=0.02), suggesting that these biomarkers may have become selectively lowered in the serotonergic dose range of venlafaxine. This is the first report of venlafaxine's possible effect on pro-inflammatory biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence for an immune response in major depression: A review and hypothesis
Maes, M. (1995) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)00101-m · Cited by 1,003
Müller, N., Schwarz, M. J., Dehning, S., Douhe, A., Cerovecki, A., Goldstein-Müller, B., Spellmann, I., Hetzel, G., Maino, K., Kleindienst, N., et al. (2006) · Molecular Psychiatry · doi:10.1038/sj.mp.4001805 · Cited by 794
Cytokine Production and Treatment Response in Major Depressive Disorder
Lanquillon, S. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00134-7 · Cited by 735 · cited 3×
“Since earlier studies had suggested that SSRIs might be unique in exerting down-immunoregulatory effects over 6 8 weeks of treatment (Lanquillon et al. 2000; Tuglu et al. 2003; Basterzi et al. 2005), it was further hypothesized that venlafaxine might fail to exert immune down-regulatory effects, as…”
BackgroundResultPratt, L. A., Ford, D. E., Crum, R. M., Armenian, H. K., Gallo, J. J., & Eaton, W. W. (1996) · Circulation · doi:10.1161/01.cir.94.12.3123 · Cited by 643 · cited 12×
“None of the subjects had symptoms or histories of CAD, nor had they ever been diagnosed as high-risk for CAD.”
BackgroundInfluentialZhu, C.-B., Blakely, R. D., & Hewlett, W. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301029 · Cited by 549 · cited 1×
“A final support for the cytokine theory of depression is that pro-inflammatory cytokines alter tryptophan metabolism and serotonin reuptake in ways that favour (e.g., lowering serotonin activity) the development of affective disorders (Palazzolo and Quadri 1992; Zhu et al. 2006).”
BackgroundTuglu, C., Kara, S. H., Caliyurt, O., Vardar, E., & Abay, E. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1566-z · Cited by 391
Th1, Th2, and Th3 cytokine alterations in major depression
MYINT, A., LEONARD, B., STEINBUSCH, H., & KIM, Y. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.07.008 · Cited by 371
Effects of antidepressants on the production of cytokines
Kenis, G., & Maes, M. (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702003164 · Cited by 370 · cited 2×
“…of non-SSRI, NRI, or SNRI, antidepressants (of which venlafaxine is an example) to down-regulate cytokines in depression have also been unclear (Kenis and Maes 2002; Tuglu et al. 2003; Kubera et al. 2004; Basterzi et al. 2005; Lee and Kim 2006; Rybakowski et al. 2006; MarquesDeak et al. 2007).”
BackgroundResultKubera, M., Lin, A.-H., Kenis, G., Bosmans, E., van Bockstaele, D., & Maes, M. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200104000-00012 · Cited by 343
Association Between Depression and Elevated C-Reactive Protein
Danner, M., Kasl, S. V., Abramson, J. L., & Vaccarino, V. (2003) · Psychosomatic Medicine · doi:10.1097/01.psy.0000041542.29808.01 · Cited by 341 · cited 3×
“The MCP-1, CD40L, and CRP biomarkers have also been studied, though to a lesser degree (Berk et al. 1997; Danner et al. 2003; Suarez et al. 2003; Leo et al. 2006).”
Background
Cited by
The Bidirectional Relationship of Depression and Inflammation: Double Trouble
Beurel, E., Toups, M., & Nemeroff, C. B. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.002 · Cited by 2,136
Berk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Haapakoski, R., Mathieu, J., Ebmeier, K. P., Alenius, H., & Kivimäki, M. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.001 · Cited by 1,129
Osimo, E. F., Pillinger, T., Rodriguez, I. M., Khandaker, G. M., Pariante, C. M., & Howes, O. D. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.02.010 · Cited by 937
“…O'brien SM, Scott LV, Dinan TG. , 2006; Nunes et al., 2011; Narita et al., 2006; Munjiza et al., 2018; Motivala et al., 2005; Mota et al., 2013; Piletz et al., 2009; Pike and Irwin, 2006; Pavón et al., 2006; Owen et al., 2001; Ogłodek, 2018; Tuglu et al., 2003; Thomas et al., 2005; Sutcigil…”
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Inflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666
Liu, J. J., Wei, Y. B., Strawbridge, R., Bao, Y., Chang, S., Shi, L., Que, J., Gadad, B. S., Trivedi, M. H., Kelsoe, J. R., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0474-5 · Cited by 429
Depression: an inflammatory illness?: Figure 1
Krishnadas, R., & Cavanagh, J. (2012) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2011-301779 · Cited by 392
The Compensatory Immune-Regulatory Reflex System (CIRS) in Depression and Bipolar Disorder
Maes, M., & Carvalho, A. F. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1016-x · Cited by 306
Leighton, S. P., Nerurkar, L., Krishnadas, R., Johnman, C., Graham, G. J., & Cavanagh, J. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.205 · Cited by 291
Kopschina Feltes, P., Doorduin, J., Klein, H. C., Juárez-Orozco, L. E., Dierckx, R. A., Moriguchi-Jeckel, C. M., & de Vries, E. F. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117711708 · Cited by 279
“(Piletz et al., 2009).”
BackgroundThe role of the innate immune system in psychiatric disorders
Jones, K. A., & Thomsen, C. (2013) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.10.002 · Cited by 274
Stuart, M. J., & Baune, B. T. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.001 · Cited by 259
A psychoneuroimmunological review on cytokines involved in antidepressant treatment response
Janssen, D. G. A., Caniato, R. N., Verster, J. C., & Baune, B. T. (2010) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1103 · Cited by 240
“A recently published study by Piletz et al. (2009) of MDD patients treated with venlafaxine, found that levels of TNF-a, IL-1b, and MCP-1 remained elevated Copyright # 2010 John Wiley & Sons, Ltd. during treatment.”
BackgroundEffect of antidepressant treatment on peripheral inflammation markers – A meta-analysis
Więdłocha, M., Marcinowicz, P., Krupa, R., Janoska-Jaździk, M., Janus, M., Dębowska, W., Mosiołek, A., Waszkiewicz, N., & Szulc, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.026 · Cited by 233
Inflammation-Associated Co-morbidity Between Depression and Cardiovascular Disease
Halaris, A. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_28 · Cited by 233
Self-citationPearson-Leary, J., Zhao, C., Bittinger, K., Eacret, D., Luz, S., Vigderman, A. S., Dayanim, G., & Bhatnagar, S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0380-x · Cited by 206
A meta-analysis of chemokines in major depression
Eyre, H. A., Air, T., Pradhan, A., Johnston, J., Lavretsky, H., Stuart, M. J., & Baune, B. T. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.02.006 · Cited by 188
Carvalho, L. A., Torre, J. P., Papadopoulos, A. S., Poon, L., Juruena, M. F., Markopoulou, K., Cleare, A. J., & Pariante, C. M. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.10.036 · Cited by 167
Hope, S., Dieset, I., Agartz, I., Steen, N. E., Ueland, T., Melle, I., Aukrust, P., & Andreassen, O. A. (2011) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2011.08.003 · Cited by 164
Horn, S. R., Long, M. M., Nelson, B. W., Allen, N. B., Fisher, P. A., & Byrne, M. L. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.016 · Cited by 129
Treatment response and cognitive impairment in major depression: Association with C-reactive protein
Chang, H. H., Lee, I. H., Gean, P. W., Lee, S.-Y., Chi, M. H., Yang, Y. K., Lu, R.-B., & Chen, P. S. (2012) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2011.07.239 · Cited by 120
Regulatory T cells increased while IL-1β decreased during antidepressant therapy
Himmerich, H., Milenović, S., Fulda, S., Plümäkers, B., Sheldrick, A. J., Michel, T. M., Kircher, T., & Rink, L. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.03.005 · Cited by 116
Martino, M., Rocchi, G., Escelsior, A., & Fornaro, M. (2012) · Current Neuropharmacology · doi:10.2174/157015912800604542 · Cited by 111
“…5-HT and NE, hormones such as cortisol, and also in cytokines such as TNFα and IL-6 (variations of which show the closest association with depression), and also IL-1β, IL-4, IL-2, IL8, IL-10 and IFN-γ, that contribute to the behavioral and immune disturbances observed in these patients [237-245].”
BackgroundKim, Y.-K., Kim, O. Y., & Song, J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.01270 · Cited by 109
Peripheral Chemokine Levels in Women with Recurrent Major Depression with Suicidal Ideation
Grassi-Oliveira, R., Brieztke, E., Teixeira, A., Pezzi, J. C., Zanini, M., Lopes, R. P., & Bauer, M. E. (2012) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462012000100013 · Cited by 91
Does escitalopram reduce neurotoxicity in major depression?
Halaris, A., Myint, A.-M., Savant, V., Meresh, E., Lim, E., Guillemin, G., Hoppensteadt, D., Fareed, J., & Sinacore, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.04.026 · Cited by 86
Mosiołek, A., Pięta, A., Jakima, S., Zborowska, N., Mosiołek, J., & Szulc, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081706 · Cited by 72
Interleukin-1 β-Targeted Treatment Strategies in Inflammatory Depression: Toward Personalized Care
Ellul, P., Boyer, L., Groc, L., Leboyer, M., & Fond, G. (2016) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12656 · Cited by 65
Targeting the CCL2-CCR2 Axis in Depressive Disorders
Curzytek, K., & Leśkiewicz, M. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00280-w · Cited by 47
Serum levels of chemokines in adolescents with major depression treated with fluoxetine.
Peña, F. R. D. L., Cruz-Fuentes, C., Palacios, L., Girón-Pérez, M. I., Medina-Rivero, E., Ponce-Regalado, M. D., Alvarez-Herrera, S., Pérez-Sánchez, G., Becerril-Villanueva, E., Maldonado-García, J. L., et al. (2020) · World Journal of Psychiatry · doi:10.5498/wjp.v10.i8.175 · Cited by 24
Metadata
- Authors
- Piletz, J. E., Halaris, A., Iqbal, O., Hoppensteadt, D., Fareed, J., Zhu, H., Sinacore, J., & DeVane, C. L.
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2009-01
- Volume
- 10
- Issue
- 4
- Pages
- 313-323
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2024969297
- Cited by
- 130
- References
- 18
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.